Showing results (341-350 of 386) with videos related to

Sort By:
Pageof 39
Endocrine-Related Cancer|April 23, 2010
Gemcitabine plus metronomic 5-fluorouracil or capecitabine as a second-/third-line chemotherapy in advanced adrenocortical carcinoma: a multicenter phase II studyPaola Sperone, Anna Ferrero, Fulvia Daffara, et al.
Cancer Treatment Reviews|December 19, 2012
Second Italian consensus conference on malignant pleural mesothelioma: state of the art and recommendationsCarmine Pinto, Silvia Novello, Valter Torri, et al.
Biomedicines|June 24, 2022
From SGAP-Model to SGAP-Score: A Simplified Predictive Tool for Post-Surgical Recurrence of PheochromocytomaMirko Parasiliti-Caprino, Fabio Bioletto, Chiara Lopez, et al.
Human Pathology|September 4, 2016
Sarcomatoid adrenocortical carcinoma: a comprehensive pathological, immunohistochemical, and targeted next-generation sequencing analysisThomas G Papathomas, Eleonora Duregon, Esther Korpershoek, et al.
International Journal of Cancer|May 9, 2020
Oncogenic properties and signaling basis of the PAX8-GLIS3 fusion geneThais Basili, Higinio Dopeso, Sarah H Kim, et al.
Cancer Cell|December 1, 2023
ALK inhibitors increase ALK expression and sensitize neuroblastoma cells to ALK.CAR-T cellsElisa Bergaggio, Wei-Tien Tai, Andrea Aroldi, et al.
Endocrine-Related Cancer|March 30, 2018
Ki67 proliferative index of the neuroendocrine component drives MANEC prognosisMassimo Milione, Patrick Maisonneuve, Alessio Pellegrinelli, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 22, 2021
The 2021 WHO Classification of Lung Tumors: Impact of Advances Since 2015Andrew G Nicholson, Ming S Tsao, Mary Beth Beasley, et al.
Journal of Cellular Physiology|September 22, 2010
Expression pattern of receptor activator of NFκB (RANK) in a series of primary solid tumors and related bone metastasesDaniele Santini, Giuseppe Perrone, Ilaria Roato, et al.
ESMO Open|February 14, 2018
Novel active agents in patients with advanced NSCLC without driver mutations who have progressed after first-line chemotherapyChristian Manegold, Alex Adjei, Federico Bussolino, et al.
Pageof 39